Statistical visualization for assessing performance of methods for safety surveillance using electronic databases

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 5, 2013, Pages 503-509

  Li, Xiaochun ^a   Hui, Siu ^a,b   Ryan, Patrick ^c   Rosenman, Marc ^a,b   Overhage, Marc ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

AUC; Electronic observational databases; Pharmacoepidemiology; Safety surveillance; Sensitivity (recall); Specificity (FPR); Statistical visualization

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; MULTIPLE REGRESSION; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; HUMANS; PHARMACOEPIDEMIOLOGY; PREDICTIVE VALUE OF TESTS; PRODUCT SURVEILLANCE, POSTMARKETING; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84877632020     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3419     Document Type: Article

References (16)

1. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 2010; 153(9): 600-606.
2. OMOP. OMOP Common Data Model (CDM) Specifications. 2009; Version 2.0.
3. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. The American Statistician 1999; 55(3): 177-202.
4. Whitaker HJ, Farrington CP, Spiessens BPM. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006; 25: 1768-1797.
5. Woodward M (ed) Epidemiology: Study design and data analysis: Chapman & Hall/CRC; 1999.
6. Madigan D. Bayesian Logistic Regression (BBR, BMR, BXR). 2004; http://www.bayesianregression.org/.
7. Norén NGHJ, Bate A, Star K, Edwards I. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Disc. 2009; 20(3): 361-387.
8. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf Oct 1997; 6(Suppl 3): S51-59.
9. Kulldorff MDR, Kolczak M, Lewis E, Lieu T, and Platt R. A Maximized Sequential Probability Ratio Test for Drug and Vaccine SafetySurveillance. 2008; http://www.populationmedicine.org/content/docs/maxSPRTsubm.pdf.
10. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology Jul 2009; 20(4): 512-522.
11. Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med 2012; 31(30): 4401-4415.
12. Ryan PB. Defining a Reference Set for Evaluating the Performance of Active Surveillance Methods. 2010; http://omop.fnih.org/OMOPWhitePapers.
13. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. PNAS. 1998; 95(25): 14863-14868.
14. Whitaker H. The self controlled case series method. BMJ 2008; 337: a1069.
15. Ryan PB. Establishing a Condition Era Persistence Window for Active Surveillance. 2010; http://omop.fnih.org/OMOPWhitePapers.
16. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227.